{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:29:50Z","timestamp":1790069390128,"version":"4.0.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":730,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Hepatitis B virus (HBV) resistance to nucleoside\/nucleotide analogs is frequent. Ultra-deep pyrosequencing (UDPS) is a powerful new tool that can detect minor viral variants and characterize complex quasispecies mixtures. We used UDPS to analyze the dynamics of adefovir-resistant HBV variants in patients with chronic HBV infection in whom adefovir resistance occurred during treatment. Amino acid substitutions known to confer resistance to adefovir were detected at baseline in most patients. The dynamics of adefovir-resistant variants were complex and differed among patients as a result of evolving differences in variant fitness. UDPS analysis revealed successive waves of selection of HBV populations with single and multiple amino acid substitutions. Adefovir-resistant variants were partially inhibited by lamivudine, but remained fit in its presence.\n                      <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>\n                      : Substitutions conferring HBV resistance to nucleoside\/nucleotide analogs exist before treatment, and that the dynamics of adefovir-resistant populations are much more complex and heterogeneous than previously thought and involve thus far unknown amino acid substitutions. The UDPS-based approach described here is likely to have important implications for the assessment of antiviral drug resistance in research and clinical practice. (Hepatology 2013;53:890\u2013901)\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.26383","type":"journal-article","created":{"date-parts":[[2013,3,15]],"date-time":"2013-03-15T18:22:35Z","timestamp":1363371755000},"page":"890-901","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":54,"title":["Characterization of the Dynamics of Hepatitis B Virus Resistance To Adefovir by Ultra-Deep Pyrosequencing"],"prefix":"10.1097","volume":"58","author":[{"given":"Christophe","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Chevaliez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bensadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Pawlotsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20241201","doi-asserted-by":"crossref","first-page":"22122219","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of agespecific HBsAg seroprevalence and endemicity.","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"R2-10-20241201","doi-asserted-by":"crossref","first-page":"S28S34","DOI":"10.1002\/hep.22975","article-title":"Epidemiology of hepatitis B in the United States.","volume":"49","author":"Kim","year":"2009","journal-title":"Hepatology"},{"key":"R3-10-20241201","doi-asserted-by":"crossref","first-page":"S45S55","DOI":"10.1002\/hep.22898","article-title":"The natural history of chronic hepatitis B virus infection.","volume":"49","author":"McMahon","year":"2009","journal-title":"Hepatology"},{"key":"R4-10-20241201","doi-asserted-by":"crossref","first-page":"448458","DOI":"10.1038\/nrgastro.2010.100","article-title":"Hepatocellular carcinoma: a global view.","volume":"7","author":"Yang","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R5-10-20241201","doi-asserted-by":"crossref","first-page":"15931608","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues.","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"R6-10-20241201","first-page":"S125S129","article-title":"The concept of hepatitis B virus mutant escape.","volume":"34","author":"Pawlotsky","year":"2005","journal-title":"J Clin Virol"},{"key":"R7-10-20241201","doi-asserted-by":"crossref","first-page":"17421751","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with directacting antiviral drugs against hepatitis C virus.","volume":"53","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"key":"R8-10-20241201","doi-asserted-by":"crossref","first-page":"37293734","DOI":"10.1128\/JCM.40.10.3729-3734.2002","article-title":"Monitoring drug resistance in chronic hepatitis B virus (HBV)infected patients during lamivudine therapy: evaluation of performance of INNOLiPA HBV DR assay.","volume":"40","author":"Lok","year":"2002","journal-title":"J Clin Microbiol"},{"key":"R9-10-20241201","doi-asserted-by":"crossref","first-page":"12831289","DOI":"10.1128\/AAC.00970-09","article-title":"Validation of the INNOLiPA HBV DR assay (version 2) in monitoring hepatitis B virusinfected patients receiving nucleoside analog treatment.","volume":"54","author":"Niesters","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-10-20241201","doi-asserted-by":"crossref","first-page":"643653","DOI":"10.1128\/JVI.80.2.643-653.2006","article-title":"Dynamics of hepatitis B virus resistance to lamivudine.","volume":"80","author":"Pallier","year":"2006","journal-title":"J Virol"},{"key":"R11-10-20241201","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1002\/hep.22634","article-title":"Complex dynamics of hepatitis B virus resistance to adefovir.","volume":"49","author":"Pallier","year":"2009","journal-title":"Hepatology"},{"key":"R12-10-20241201","doi-asserted-by":"crossref","first-page":"703712","DOI":"10.1002\/hep.21290","article-title":"Evolution of multidrug resistant hepatitis B virus during sequential therapy.","volume":"44","author":"Yim","year":"2006","journal-title":"Hepatology"},{"key":"R13-10-20241201","doi-asserted-by":"crossref","first-page":"12531261","DOI":"10.1053\/j.gastro.2006.08.013","article-title":"Selection of a multiple drugresistant hepatitis B virus strain in a livertransplanted patient.","volume":"131","author":"Villet","year":"2006","journal-title":"Gastroenterology"},{"key":"R14-10-20241201","doi-asserted-by":"crossref","first-page":"376380","DOI":"10.1038\/nature03959","article-title":"Genome sequencing in microfabricated highdensity picolitre reactors.","volume":"437","author":"Margulies","year":"2005","journal-title":"Nature"},{"key":"R15-10-20241201","doi-asserted-by":"crossref","first-page":"856866","DOI":"10.1373\/clinchem.2008.107565","article-title":"Metagenomic pyrosequencing and microbial identification.","volume":"55","author":"Petrosino","year":"2009","journal-title":"Clin Chem"},{"key":"R16-10-20241201","first-page":"12751285","article-title":"Ultradeep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reversetranscriptase inhibitor (NRTI)treated patients and NRTInaive patients.","volume":"199","author":"MargeridonThermet","year":"2009","journal-title":"J Infect Dis"},{"key":"R17-10-20241201","doi-asserted-by":"crossref","first-page":"17181726","DOI":"10.1128\/JVI.02011-08","article-title":"Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drugresistant and drugnaive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen.","volume":"83","author":"Solmone","year":"2009","journal-title":"J Virol"},{"key":"R18-10-20241201","doi-asserted-by":"crossref","first-page":"17431751","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Longterm therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years.","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"R19-10-20241201","doi-asserted-by":"crossref","first-page":"18631871","DOI":"10.1002\/hep.22250","article-title":"Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to 18 years) with chronic hepatitis B.","volume":"47","author":"Jonas","year":"2008","journal-title":"Hepatology"},{"key":"R20-10-20241201","doi-asserted-by":"crossref","first-page":"230237","DOI":"10.1002\/hep.510290119","article-title":"Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance.","volume":"29","author":"Pichoud","year":"1999","journal-title":"Hepatology"},{"key":"R21-10-20241201","doi-asserted-by":"crossref","first-page":"513516","DOI":"10.1038\/35035083","article-title":"An SNP map of the human genome generated by reduced representation shotgun sequencing.","volume":"407","author":"Altshuler","year":"2000","journal-title":"Nature"},{"key":"R22-10-20241201","doi-asserted-by":"crossref","first-page":"195197","DOI":"10.1016\/0022-2836(81)90087-5","article-title":"Identification of common molecular subsequences.","volume":"147","author":"Smith","year":"1981","journal-title":"J Mol Biol"},{"key":"R23-10-20241201","doi-asserted-by":"crossref","first-page":"1308113086","DOI":"10.1073\/pnas.0801523105","article-title":"Subclonal phylogenetic structures in cancer revealed by ultradeep sequencing.","volume":"105","author":"Campbell","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R24-10-20241201","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1038\/nrg2626","article-title":"Sequencing technologiesthe next generation.","volume":"11","author":"Metzker","year":"2010","journal-title":"Nat Rev Genet"},{"key":"R25-10-20241201","doi-asserted-by":"crossref","first-page":"13031313","DOI":"10.1053\/j.gastro.2012.02.027","article-title":"New virologic tools for management of chronic hepatitis B and C.","volume":"142","author":"Chevaliez","year":"2012","journal-title":"Gastroenterology"},{"key":"R26-10-20241201","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1471-2180-12-96","article-title":"Detection of mixed populations of wildtype and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients.","volume":"12","author":"Mello","year":"2012","journal-title":"BMC Microbiol"},{"key":"R27-10-20241201","doi-asserted-by":"crossref","first-page":"e37874","DOI":"10.1371\/journal.pone.0037874","article-title":"Ultradeep pyrosequencing detects conserved genomic sites and quantifies linkage of drugresistant amino acid changes in the hepatitis B virus genome.","volume":"7","author":"RodriguezFrias","year":"2012","journal-title":"PLoS One"},{"key":"R28-10-20241201","doi-asserted-by":"crossref","first-page":"747755","DOI":"10.1016\/j.jhep.2008.01.027","article-title":"Impact of hepatitis B virus rtA181VT mutants on hepatitis B treatment failure.","volume":"48","author":"Villet","year":"2008","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"R29-10-20241201","first-page":"A100","article-title":"HIV1 coreceptor usage prediction by ultradeep pyrosequencing increases the rate of patients treated with success by CCR5 antagonists.","volume":"16","author":"Rodriguez","year":"2011","journal-title":"Antiviral Ther"},{"issue":"Suppl 1","key":"R30-10-20241201","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0168-8278(11)60069-X","article-title":"Molecular characterization of HCV resistance to telaprevir by means of ultradeep pyrosequencing: preexisting resistant variants and dynamics of resistant populations.","volume":"54","author":"Chevaliez","year":"2011","journal-title":"J Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26383","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201309000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T09:08:26Z","timestamp":1733044106000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201309000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26383","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}